Quoin Pharma maps multi-indication clinical push for QRX009 rapamycin
Quoin Pharmaceuticals has outlined a broad clinical expansion for QRX009, its topical rapamycin lotion, with investigator-led studies planned in Pachyonychia Congenita (PC), Gorlin Syndrome (GS), and Tuberous Sclerosis Complex (TSC) — all rare dermatological conditions with limited or no approved therapies. The NASDAQ-listed company also confirmed it is on track to submit an Investigational New Drug Application (IND) to the US Food and Drug Administration for QRX009 in a separate, as-yet-unnamed indication by Q3 2026.
The PC study will be led by Professor Edel O'Toole of Queen Mary University of London, a specialist in rare skin diseases with prior clinical trial experience in the condition. Quoin said it intends to start this first study in Q3 2026, with the GS and TSC studies to follow later in the year. If the programme proceeds to schedule, the company says QRX009 could be in active clinical evaluation across four distinct indications before year-end.
Pipeline context
QRX009 sits alongside QRX003, Quoin's lead candidate targeting Netherton Syndrome, for which the company is advancing towards pivotal trials. A second IND, covering Peeling Skin Syndrome, is also targeted for Q3 2026. Chief executive Michael Myers described the multi-indication strategy as "highly complementary," though no interim data from any QRX009 programme have yet been disclosed publicly.
Rapamycin (sirolimus) is an mTOR inhibitor with an established systemic safety profile, and its topical application in rare dermatoses is an area of growing academic and commercial interest. Several academic centres have published investigator-initiated studies using off-label topical sirolimus formulations in conditions including TSC-associated angiofibromas, lending some biological plausibility to Quoin's approach. The proprietary delivery system — described by the company as capable of loading rapamycin at 4% and 5% concentrations in lotion and dermal patch formats — is positioned as a differentiating factor over earlier, lower-concentration formulations, though head-to-head comparison data have not been presented.
Competitive and regulatory landscape
The rare skin disease space is relatively sparsely populated at the clinical stage, with most large dermatology players focused on inflammatory conditions such as atopic dermatitis and psoriasis. Orphan drug designations — which the FDA grants for conditions affecting fewer than 200,000 patients in the US — would be relevant for PC, GS, and TSC, offering seven-year market exclusivity and potential for priority review vouchers. Quoin has established relationships with patient advocacy organisations including The PC Project and the Gorlin Syndrome Alliance, which typically assist with trial recruitment in ultra-rare populations.
From a regulatory standpoint, the FDA has shown willingness to accept adaptive and basket-style trial designs for rare diseases, and the agency's Office of Orphan Products Development provides additional guidance pathways. Investigator-led studies, while useful for generating early proof-of-concept data, are not themselves sufficient for regulatory approval; Quoin will ultimately need company-sponsored trials with pre-agreed endpoints to support any New Drug Application. Investors will therefore be watching closely to see whether the IND filing due in Q3 — covering the undisclosed fourth indication — is accompanied by a company-sponsored protocol with a defined primary endpoint and sample-size rationale.
The breadth of Quoin's stated ambitions for 2026 is notable for a small-cap company, and execution risk across several simultaneous programmes will be a key consideration for the market.